Ligand Pharmaceuticals | LGND - Debt


Ligand Pharmaceuticals reported $451.98M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Agenus USD 35.54M 2.34M Mar/2025
Amgen USD 57.32B 2.72B Mar/2026
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 989.46M 676.69M Mar/2026
Baxter International USD 9.69B 93M Mar/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Eli Lilly USD 43.37B 867M Mar/2026
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Enviri Corporation USD 1.44B 3.08M Dec/2024
Gilead Sciences USD 22.17B 2.76B Mar/2026
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Glaxosmithkline GBP 19.06B 1.31B Mar/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Insmed USD 725.8M 1.82M Jun/2026
Intrexon USD 0 13.82M Jun/2024
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Ligand Pharmaceuticals USD 451.98M 486K Mar/2026
MacroGenics USD 36.51M 500K Mar/2026
Merck USD 49.12B 222M Mar/2026
Pacira USD 363.12M 4.53M Jun/2026
Pfizer USD 63.73B 231M Mar/2026
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
Sangamo BioSciences USD 0 0 Jun/2022
Veracyte USD 39.33M 321K Mar/2026